Eight Weeks of Mindfulness Training Moved the Brain's Answer to a Drug Cue

The strangest part of the study is the film clip. Participants lay in an MRI scanner at Mount Sinai and watched drug-related scenes from Trainspotting while the machine recorded which parts of their prefrontal cortex lit up in step with everyone else's.

That measure — how similarly two brains respond to the same footage, second by second — is normally the province of media neuroscience. Here it was used to test whether eight weeks of group therapy changes the way a person's brain handles a reminder of opioid use. The answer, published Oct. 28 in JAMA Psychiatry, is that it does, at least in 86 people treated at a single residential facility in New York City.

The trial matters less for the size of the effect than for what it demonstrates about the target. Medications for opioid use disorder keep people alive and suppress withdrawal, but neither methadone nor buprenorphine is designed to retrain the brain's response to a cue. A therapy that measurably shifts prefrontal function gives the field something it has mostly argued about in theory: a mechanism.

Eighty-Six People, Two Kinds of Group Therapy

Every participant had opioid use disorder and was already stabilized on methadone or buprenorphine at a long-term inpatient program run by Samaritan Daytop Village. They were randomly assigned to one of two eight-week group treatments: Mindfulness-Oriented Recovery Enhancement, known as MORE, or psychoeducational supportive therapy.

That comparison arm is the detail worth pausing on, because it is stronger than the usual "treatment as usual." The control condition was matched for duration and group format, so the trial did not simply test whether getting eight weeks of extra attention helps. Both groups got the same amount of time with a facilitator, in the same group shape. What differed was the content.

The design rests on the impaired response inhibition and salience attribution model, which holds that in addiction, drug cues capture disproportionate attention and value while the capacity to override the pull weakens. The researchers focused on two nodes of that system: the lateral prefrontal cortex, implicated in regulating craving, and the ventromedial prefrontal cortex, which assigns value to rewards — drug rewards and ordinary ones alike.

Participants were scanned before treatment began and again at the end. This was, according to the research team, the first randomized clinical trial to use functional MRI to examine how a mindfulness-based intervention changes brain function in addiction.

What the Scanner Saw When Cues Were Reappraised

Inside the scanner, participants were shown images related to drug use and asked to reinterpret them in a way that reduced their emotional force — a deliberate cognitive maneuver, not a passive exposure.

The MORE group showed less drug-related activity in the lateral prefrontal cortex during that reappraisal than the comparison group did. Read plainly: the region that normally works overtime in the presence of a drug cue was doing less drug-biased work, in people who had been taught to reframe the image.

The Savoring Signal

The second task moved in the opposite direction. Participants were shown images of appetizing food and asked to savor them — to attend to the positive experience rather than let it slide past.

Within the MORE group, two changes predicted how much craving fell. A larger shift in prefrontal response to drug cues, and a bigger increase in ventromedial prefrontal activity while savoring the food images, both tracked greater reductions in craving. The reward system was being pulled back toward ordinary pleasures, and the person reported wanting opioids less.

That pairing is the most clinically suggestive result in the paper, because it describes a substitution rather than a suppression. Nothing in the protocol asked participants to care less about reward. It asked them to care about different rewards.

The Movie Measured Shared Attention

The Trainspotting task came at the problem from a third angle. Instead of asking each person to regulate, the researchers let the footage do the work and then compared brain activity across participants — inter-subject correlation, a measure of how tightly a group's medial prefrontal responses lock together while watching the same thing.

Participants who received MORE showed less synchronized medial prefrontal activity during the drug scenes than those in the comparison group. Across everyone in the study, the bigger the drop in that synchrony, the bigger the drop in craving triggered by the scenes.

The authors argue that realistic film clips may catch something staged images miss: the automatic, bottom-up reactivity that a drug reminder produces before any deliberate regulation begins. It is also, quietly, an argument for better measurement tools. A photograph of a syringe is a narrow probe of a much wider problem.

Craving Fell, and Abstinence Held at Four Months

Roughly four months after treatment ended, participants who had received MORE showed greater increases in the duration of abstinence than those who received the comparison therapy.

That follow-up is what keeps the paper from being a pure imaging exercise. Craving is a subjective report, and brain maps are expensive; the outcome that matters to a patient is whether they are still not using months later. The trial reports both, and they point the same direction.

"The prefrontal cortex sits at the top of the brain's hierarchy for self-control and for assigning value to our experiences, and in addiction these functions are hijacked by drug cues at the expense of other rewards," said Rita Z. Goldstein, PhD, Mount Sinai Professor in Neuroimaging of Addiction at the Icahn School of Medicine at Mount Sinai and the paper's senior author. "Showing that two months of a behavioral treatment can begin to restore this balance tells us that prefrontal function in addiction is not fixed, and that recovery of brain function is possible."

What MORE Is, and What It Isn't

MORE was developed by Eric L. Garland, PhD, of the University of California San Diego, and combines three practices across the eight weeks. Mindfulness training builds attention to the present moment. Cognitive reappraisal teaches people to reinterpret triggers. Savoring trains attention on ordinary positive experience — the third component that the food-image task was built to measure.

In this trial it was an addition to medication, not an alternative. Every participant was on methadone or buprenorphine throughout, and the framing matters in a field where behavioral approaches have sometimes been sold as a way around medication-assisted treatment, when the evidence supports the opposite arrangement.

"Medications for opioid use disorder save lives, but they are not designed to retrain how the brain responds to the cues that trigger craving," said first author Yuefeng Huang, PhD, a postdoctoral fellow in the Department of Psychiatry at Icahn Mount Sinai at the time of the study and now starting a lab at the Institute for Human Neuroscience at Boys Town National Research Hospital in Nebraska. He described the shift as freeing brain resources that drug cues had monopolized, so that "people can once again enjoy everyday non-drug rewards."

The Limits the Announcement Doesn't Dwell On

Eighty-six people in one residential program is a mechanism study, not a population estimate, and the paper's authors say so. They call for larger and more diverse samples, and they note a specific gap: the trial needs more women before anyone can say whether sex-related and hormonal factors change the response. Behavioral therapy cannot be blinded — participants knew which group they were in, and so, presumably, did the facilitators.

Two limits are less obvious and more consequential.

The first concerns what "duration of abstinence" means at four months in a long-term residential setting. Time not using is partly a function of time still in treatment, and the paper does not report whether MORE changed retention. If the therapy kept people in the program longer, some of the abstinence difference is an engagement effect wearing a clinical label.

The second concerns the imaging analysis. The trial pre-specified two regions from a model, which is good practice and limits fishing — but it also means anything happening outside those two nodes went unexamined. And the brain-behavior findings are associations within the MORE group, not a formal test that the brain change caused the craving change. The story is coherent; it is not yet causal.

What survives all of that is the direction. A behavioral intervention delivered in a group room, by facilitators rather than scanners, altered prefrontal responses in the direction the theory predicted, and those alterations traveled with how much less people craved. For a condition where the pharmacological toolkit is strong and the psychological one has been thin on mechanism, that is a meaningful addition.

Where the Evidence Goes Next

The Mount Sinai team is already testing two ways to push the same circuitry harder. One combines transcranial direct current stimulation — a weak electrical current applied to the scalp — with cognitive reappraisal training. The other uses real-time fMRI neurofeedback, in which people watch their own brain activity and learn to modulate the shared prefrontal response the movie task detected.

Neither is close to a clinic. What is close is the therapy itself, and this is where the study's practical value sits: MORE requires a trained facilitator and eight group sessions, not a magnet. Programs that already run groups for opioid use disorder could deliver it. The scanner was the instrument that proved the mechanism, not a requirement for using it.

The study was supported by the National Center for Complementary and Integrative Health (grant R01AT010627), with additional support from the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Center for Advancing Translational Sciences.